AAA
CYTK icon

Affinity Asset Advisors’s Cytokinetics CYTK Stock Holding History

Affinity Asset Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.9M Sell
550,000
-150,483
-21% -$10.8M 2.12% 12
2026
Q1 		$46.2M Sell
700,483
-99,517
-12% -$6.32M 2.38% 12
2025
Q4 		$50.8M Buy
800,000
+450,000
+129% +$28M 2.9% 9
2025
Q3 		$19.2M Buy
+350,000
New +$14.4M 1.68% 20
2024
Q2 		– Sell
-80,000
Closed -$5.61M – 107
2024
Q1 		$5.61M Sell
80,000
-80,000
-50% -$6.19M 0.69% 44
2023
Q4 		$13.4M Sell
160,000
-70,366
-31% -$2.55M 2.44% 15
2023
Q3 		$6.79M Buy
230,366
+105,218
+84% +$3.5M 1.91% 17
2023
Q2 		$4.08M Sell
125,148
-96,315
-43% -$3.56M 1.43% 24
2023
Q1 		$7.79M Buy
221,463
+133,862
+153% +$5.46M 2.57% 11
2022
Q4 		$4.01M Buy
87,601
+22,601
+35% +$972K 1.57% 23
2022
Q3 		$3.15M Buy
65,000
+50,000
+333% +$2.41M 0.88% 34
2022
Q2 		$589K Buy
+15,000
New +$604K 0.25% 45
2022
Q1 		– Sell
-145,552
Closed -$6.63M – 65
2021
Q4 		$6.63M Buy
145,552
+20,552
+16% +$793K 2.41% 17
2021
Q3 		$4.47M Buy
125,000
+55,000
+79% +$1.62M 1.13% 23
2021
Q2 		$1.39M Buy
70,000
+30,000
+75% +$704K 0.5% 46
2021
Q1 		$930K Sell
40,000
-30,000
-43% -$641K 0.32% 49
2020
Q4 		$1.46M Buy
+70,000
New +$1.28M 0.77% 34

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Affinity Asset Advisors's CYTK Position: Q2 2026 in Review

Affinity Asset Advisors reduced its Cytokinetics (CYTK) stake by 21% in Q2 2026, selling an estimated $10.8M and leaving 550,000 shares worth $46.9M. The position accounts for 2.12% of the portfolio, ranked #12.

Affinity Asset Advisors first reported a position in CYTK in Q4 2020 and has held it in 17 quarters since. The position peaked at $50.8M in Q4 2025. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Affinity Asset Advisors held 550,000 shares of Cytokinetics worth $46.9M as of Q2 2026.
  • Affinity Asset Advisors sold 150,483 Cytokinetics shares in Q2 2026, an estimated $10.8M.
  • Cytokinetics made up 2.12% of Affinity Asset Advisors's portfolio in Q2 2026, its #12 holding.
  • Affinity Asset Advisors first reported a position in Cytokinetics in Q4 2020 and has held it in 17 quarters since.
  • Affinity Asset Advisors's Cytokinetics position peaked at $50.8M in Q4 2025.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.